Major depressive disorder (MDD) is an important cause of disability worldwide.
1 Insufficient response rates, persistent residual symptoms, frequent relapse or recurrence of symptoms constitute unsatisfactory outcomes of conventional antidepressant treatments. Response rates for an initial treatment are estimated at roughly 50% with a substantial proportion lacking full remission even following various switching and augmentation strategies of the antidepressant regimen.
2